European Commission Approves Pfizer’s HYMPAVZI (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors Read more
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform Read more
Datopotamab Deruxtecan BLA Submitted for Accelerated Approval in the U.S. for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Read more
Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan Read more
Apollo Therapeutics Signs Exclusive Ex-China License From Sunshine Lake Pharma for Clinical-Stage FGF21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications Read more
Ontada Collaborates with Datavant to Enable Faster Access to Market-Leading Oncology Insights Read more
Ojjaara (momelotinib) approved in Canada for the treatment of myelofibrosis in adults who have moderate to severe anemia Read more